Alnylam’s Givlaari, Novo’s Rybelsus among CHMP’s latest recommendations
Among a series of recommendations issued Friday, EMA’s CHMP backed approval of what would be Alnylam’s second approved RNAi drug in the EU, as well as an oral diabetes therapy that Novo Nordisk is relying on to spur growth.
The committee’s recommendations